A literature review of the promising future of TROP2: a potential drug therapy target

Ying Wen; Dengjie Ouyang; Qiongyan Zou; Qitong Chen; Na Luo; Hongye He; Munawar Anwar; Wenjun Yi

doi:10.21037/atm-22-5976

A literature review of the promising future of TROP2: a potential drug therapy target

Ann Transl Med. 2022 Dec;10(24):1403. doi: 10.21037/atm-22-5976.

Authors

Ying Wen¹, Dengjie Ouyang², Qiongyan Zou¹, Qitong Chen¹, Na Luo¹, Hongye He¹, Munawar Anwar¹, Wenjun Yi¹

Affiliations

¹ Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
² Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China.

Abstract

Background and objective: Previous studies have demonstrated that the oncogene trophoblast cell surface antigen 2 (TROP2) has great application prospects as a therapeutic target. However, few literature reviews have systematically summarized and evaluated its role in cancer therapy. This study aims to summarize the molecular structure, functions, signal transduction pathways, and prognostic value of TROP2, and explore therapeutic agents that target TROP2.

Methods: A total of 1,376 published literatures from PubMed and 614 published literatures from EMBASE were retrieved by searching "TROP2" or "Trophoblast cell surface antigen 2". The search was conducted on December 12, 2020, and updated on November 20, 2022. The cBioportal and GEPIA (Gene Expression Profiling Interactive Analysis) databases were used to analyze the expression, mutation, and prognostic value of TROP2 in different types of cancer.

Key content and findings: TROP2 is overexpressed in different tumor tissues and plays roles in cell proliferation, invasion, migration, apoptosis, and treatment resistance by binding to or interacting with several molecules. As a therapeutic target, TROP2 is particularly suitable for antibody-based therapies. Monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), virus-like particles, and antibody drugs in combination with traditional chemotherapy, immunotherapy, radioimmunotherapy, photoimmunotherapy, and nanoparticles that target TROP2 have thus far been rapidly developed. For example, sacituzumab govitecan (IMMU-132), a TROP2-targeting ADC, was granted accelerated approval for the treatment of metastatic triple-negative breast cancer (TNBC). Anti-TROP2 antibody-conjugated nanoparticles (ST-NPs) are a promising vehicle for delivering doxorubicin in targeted TNBC therapy.

Conclusions: The availability of TROP2-targeting ADCs makes TROP2 an accessible and promising therapeutic target for advanced metastatic cancers. The present review describes the important role of TROP2 in tumorigenesis and its potential applications as a promising biomarker and therapeutic target that is capable of reversing resistance.

Keywords: TACSTD2; TROP2; TROP2 antibody; TROP2-targeted therapy; antibody-drug conjugates (ADCs).

Publication types

Review